Federal Register / Vol. 74, No. 38 / Friday, February 27, 2009 / Notices 8975 

contacting NICEATM (see FOR FURTHER

INFORMATION CONTACT above). 

Attendance and Registration 

In order to facilitate planning for this 

meeting, persons wishing to attend are 

asked to register by April 14, 2009, via 

the NICEATM–ICCVAM Web site 

(http://iccvam.niehs.nih.gov/contact/ 

reg_LLNAPanel.htm). Visitor parking is 

located in the multi-level parking garage 

accessible via NIH Gateway Drive. All 

visitors should proceed to the Gateway 

Center to receive a visitor badge. Note: 

parking is limited and a governmentissued ID is required for access (an area 

map, driving directions, and NIH 

contact information are available at 

http://www.nih.gov/about/visitor/ 

index.htm). 

Availability of the Revised Documents 

The revised draft BRDs and revised 

draft ICCVAM test method 

recommendations will be available from 

the NICEATM–ICCVAM Web site 

(http://iccvam.niehs.nih.gov/methods/ 

immunotox/llna_PeerPanel.htm) by 

March 3, 2009, or by contacting 

NICEATM (see FOR FURTHER

INFORMATION CONTACT above). 

Request for Public Comments 

NICEATM invites the submission of 

written comments on the revised draft 

BRDs and revised draft ICCVAM test 

method recommendations and prefers 

that comments be submitted by April 

14, 2009, electronically via the 

NICEATM–ICCVAM Web site http:// 

iccvam.niehs.nih.gov/contact/ 

FR_pubcomment.htm or via e-mail at 

niceatm@niehs.nih.gov. Written 

comments may also be sent by mail, fax, 

or e-mail to Dr. William Stokes, Director 

of NICEATM, at the address listed above 

(see FOR FURTHER INFORMATION CONTACT). 

When submitting written comments, 

please refer to this Federal Register 

notice and include appropriate contact 

information (name, affiliation, mailing 

address, phone, fax, e-mail, and 

sponsoring organization, if applicable). 

All comments received will be placed 

on the NICEATM–ICCVAM Web site 

(http://iccvam.niehs.nih.gov), and 

identified by the individual’s name and 

affiliation or sponsoring organization (if 

applicable). Comments will also be 

provided to the Panel and ICCVAM 

agency representatives, and made 

available at the meeting. 

Time will be provided for the 

presentation of oral comments by the 

public at designated times during the 

peer review. Members of the public who 

wish to present oral statements at the 

meeting (one speaker per organization) 

should contact NICEATM (see FOR

FURTHER INFORMATION CONTACT above) by 

April 14, 2009 and provide a written 

copy of their comments. Each speaker is 

asked to provide contact information 

(name, affiliation, mailing address, 

phone, fax, e-mail, and sponsoring 

organization, if applicable) when 

registering to make oral comments. Up 

to seven minutes will be allotted per 

speaker. If this is not possible, please 

bring 40 copies of your comments to the 

meeting for distribution and to 

supplement the record. Written 

statements can supplement and expand 

the oral presentation. Please provide 

NICEATM with copies of any 

supplementary written statement using 

the guidelines outlined above. 

Summary minutes and the Panel’s 

final report will be available following 

the meeting on the NICEATM–ICCVAM 

Web site (http://iccvam.niehs.nih.gov). 

ICCVAM will consider the Panel’s 

conclusions and recommendations and 

any public comments received in 

finalizing their test method 

recommendations and performance 

standards for these methods. 

Background Information on ICCVAM, 

NICEATM, and the Scientific Advisory 

Committee on Alternative Toxicological 

Methods (SACATM) 

ICCVAM is an interagency committee 

composed of representatives from 15 

Federal regulatory and research agencies 

that use, generate, or disseminate 

toxicological information. ICCVAM 

conducts technical evaluations of new, 

revised, and alternative methods with 

regulatory applicability and promotes 

the scientific validation and regulatory 

acceptance of toxicological test methods 

that more accurately assess the safety 

and hazards of chemicals and products 

and that refine, reduce, and replace 

animal use. The ICCVAM Authorization 

Act of 2000 (42 U.S.C. 285l–3) 

established ICCVAM as a permanent 

interagency committee of the NIEHS 

under NICEATM. NICEATM 

administers ICCVAM and provides 

scientific and operational support for 

ICCVAM-related activities. NICEATM 

and ICCVAM work collaboratively to 

evaluate new and improved test 

methods applicable to the needs of U.S. 

Federal agencies. Additional 

information about ICCVAM and 

NICEATM can be found on their Web 

site (http://iccvam.niehs.nih.gov). 

SACATM was established January 9, 

2002, and is composed of scientists from 

the public and private sectors (67 FR 

11358). SACATM provides advice to the 

Director of the NIEHS, to ICCVAM, and 

to NICEATM regarding the statutorilymandated duties of ICCVAM and 

activities of NICEATM. Additional 

information about SACATM, including 

the charter, roster, and records of past 

meetings, can be found at http:// 

ntp.niehs.nih.gov/; see ‘‘Advisory Board 

& Committees’’ (or directly at http:// 

ntp.niehs.nih.gov/go/167). 

Dated: February 19, 2009. 

John R. Bucher, 

Associate Director, NTP. 

[FR Doc. E9–4280 Filed 2–26–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Unsolicited Multi-Project 

(P01) Grant Applications. 

Date: March 20, 2009. 

Time: 11 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700– 

B Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Roberta Binder, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, NIAID, 6700B 

Rockledge Drive, Rm 2155, Bethesda, MD 

20892, 301–496–7966, rb169n@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 20, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–4191 Filed 2–26–09; 8:45 am] 

BILLING CODE 4140–01–P 


rwilkins on PROD1PC63 with NOTICES2